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Abstract
Background: Neuroinflammation is associated with a wide range of neurodegenerative disorders, however the
specific contribution to individual disease pathogenesis and selective neuronal cell death is not well understood.
Inflammatory cerebellar ataxias are neurodegenerative diseases occurring in various autoimmune/inflammatory
conditions, e.g. paraneoplastic syndromes. However, how inflammatory insults can cause selective cerebellar
neurodegeneration in the context of these diseases remains open, and appropriate animal models are lacking. A
key regulator of neuroinflammatory processes is the NF-κB signalling pathway, which is activated by the IκB kinase
2 (IKK2) in response to various pathological conditions. Importantly, its activation is sufficient to initiate
neuroinflammation on its own.
Methods: To investigate the contribution of IKK/NF-κB-mediated neuroinflammation to neurodegeneration, we
established conditional mouse models of cerebellar neuroinflammation, which depend either on the tetracycline-
regulated expression of IKK2 in astrocytes or Cre-recombination based IKK2 activation in Bergmann glia.
Results: We demonstrate that IKK2 activation for a limited time interval in astrocytes is sufficient to induce
neuroinflammation, astrogliosis and loss of Purkinje neurons, resembling the pathogenesis of inflammatory
cerebellar ataxias. We identified IKK2-driven irreversible dysfunction of Bergmann glia as critical pathogenic event
resulting in Purkinje cell loss. This was independent of Lipocalin 2, an acute phase protein secreted by reactive
astrocytes and well known to mediate neurotoxicity. Instead, downregulation of the glutamate transporters EAAT1
and EAAT2 and ultrastructural alterations suggest an excitotoxic mechanism of Purkinje cell degeneration.
Conclusions: Our results suggest a novel pathogenic mechanism how diverse inflammatory insults can cause
inflammation/autoimmune-associated cerebellar ataxias. Disease-mediated elevation of danger signals like TLR
ligands and inflammatory cytokines in the cerebellum activates IKK2/NF-κB signalling in astrocytes, which as a
consequence triggers astrogliosis-like activation of Bergmann glia and subsequent non-cell-autonomous Purkinje
cell degeneration. Notably, the identified hit and run mechanism indicates only an early window for therapeutic
interventions.
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Background
Neuroinflammation is found in many neurological disor-
ders, including Alzheimer’s disease and autoimmune dis-
eases like multiple sclerosis and paraneoplastic
syndromes [1, 2]. Despite intensive research, the contri-
bution of neuroinflammation to the pathogenesis of
these disorders and underlying mechanisms accounting
for selective vulnerability of specific neuronal popula-
tions remain poorly understood.
During neuroinflammation, both immune cells and
neural cells respond to and produce diverse mediators,
creating a complex cross-talk which can culminate in ei-
ther neuroprotection or neurodegeneration [2]. Astrocytes
are key players in this neuro-immune crosstalk as they de-
tect and respond to various alterations of CNS homeosta-
sis. In response to pathological conditions astrocytes start
to express proinflammatory factors that mediate recruit-
ment and activation of immune cells [3]. This activation
process called astrogliosis is characterized by astrocyte
hypertrophy, proliferation, and enhanced expression of
the astroglial intermediate filament GFAP. It also alters
the homeostatic functions of astrocytes, like the uptake of
glutamate to prevent neurotoxic extracellular accumula-
tion [4]. Although astrogliosis can have beneficial func-
tions, it often impairs neural homeostasis and
regeneration after injury [4].
Astrocyte activation can be mediated by a large reper-
toire of receptors that induce various signalling path-
ways, including the IKK/NF-κB system, a master
regulator of inflammation [5]. NF-κB is activated by pro-
inflammatory stimuli like TNFα, IL-1β or TLR ligands
and regulates a large number of genes involved in in-
flammation, proliferation, cell survival, and specific CNS
functions [6, 7]. Most NF-κB activating pathways con-
verge in the activation of the IκB kinase (IKK) complex,
with IKK2 as crucial kinase subunit that induces degrad-
ation of NF-κB inhibitor proteins of the IκB family. This
results in the nuclear translocation of NF-κB dimers,
where they regulate transcription of target genes [8].
Since NF-κB activation is a key step in inflammatory
responses and astrocytes play a prominent role in such
processes in the CNS, the functional investigation of
IKK/NF-κB signalling in astrocytes is important for the
understanding and treatment of disorders associated
with neuroinflammation. Repression of NF-κB activation
in astrocytes reduced neuroinflammation in spinal cord
injury, retinal ischemia reperfusion injury, and auto-
immune encephalitis [9–13]. We have recently shown
that genetic IKK2/NF-κB activation in astrocytes is suffi-
cient to initiate neuroinflammation, resulting in develop-
mental hydrocephalus formation [14].
Here, we take advantage of this conditional model to
investigate the consequences of neuroinflammation in
adult mice on cerebellar homeostasis. We provide
evidence that astrocyte-driven neuroinflammation in the
cerebellum induces selective, non-cell-autonomous de-
generation of Purkinje neurons. This process is triggered
by activation-induced dysfunction of Bergmann glia, a
specialized astrocyte population in the cerebellum.
Results
IKK2-mediated chronic neuroinflammation results in
progressive cerebellar atrophy and ataxia
To investigate the impact of neuroinflammation on CNS
homeostasis in the adult mouse, we used a previously
established conditional mouse model that allows expres-
sion of a constitutively active IKK2 allele in astrocytes in
a doxycycline-dependent manner [14]. This gain-of-
function mouse model (GFAP.tTA/tetO.IKK2-CA, ab-
breviated IKK2-CA from hereon) is characterized by a
robust neuroinflammatory phenotype with lethal hydro-
cephalus formation in early postnatal development [14].
When IKK2-CA transgene expression is switched off
during early postnatal development by doxycycline ad-
ministration and activated later by doxycycline with-
drawal at the age of 4 weeks, animals also develop
neuroinflammation [14, 15] that initially results only in
transient, usually mild signs of sickness (data not
shown). However, after permanent transgene expression
until the age of 7–8 months, animals displayed severe
ataxia-like motor impairments in rotarod and beam-
walking tests (Fig. 1a and b).
The main control centre for motor coordination is the
cerebellum, which displayed severe atrophy at 36 weeks
of age (Fig. 1c). MRI analysis at 50 weeks confirmed the
severe cerebellar atrophy, whereas it did not reveal any
obvious alterations in other brain regions (Fig. 1d).
Measurement of the rostro-caudal length of the cerebel-
lum in different age groups showed an onset of atrophy
around the age of 12 weeks (Fig. 1e). At 20 weeks the
majority of animals display severe atrophy indicating
rapid progression of degeneration (Fig. 1e). Remarkably,
motor deficits are already present at 10 weeks, indicating
earlier subtle cerebellar deficits preceding macroscopic
atrophy (Additional file 1: Figure S1A).
Nissl staining did not reveal cerebellar alterations
at the age of 8 weeks, i.e. before onset of macro-
scopic atrophy, but a prominent compression of the
cerebellar cortex, especially the molecular layer, was
observed at 36 weeks (Additional file 1: Figure S1B).
This was associated with a prominent loss of
Purkinje neurons, accumulation of cells in the men-
ingeal zone and in severe cases also with a loss of
cells in the internal granule layer (Fig. 1f ). Purkinje
cell loss at different ages (8–36 weeks) in the simple
lobule correlated with the time course of cerebellar
atrophy (Fig. 1g). The extent of degeneration is
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comparable throughout the cerebellum, e.g. the para-
median lobule shows cell loss similar to the simple
lobule (Fig. 1h).
When we expressed IKK2-DN, a kinase inactive allele
of IKK2 [16], in astrocytes, no cerebellar degeneration
was observed (Additional file 1: Figure S1C and D) indi-
cating that the phenotype is dependent on IKK2 kinase
activity.
Cerebellar neuroinflammation involves local glial
responses and infiltration of peripheral immune cells
To address the mechanisms leading to selective cerebellar
neurodegeneration we performed a detailed analysis of the
inflammatory response elicited by IKK2 activation in as-
trocytes. At the age of 8 weeks when there is no obvious
cerebellar degeneration, we did not observe significant in-
flammatory infiltration in the cerebellum (Fig. 2a).
Fig. 1 Expression of constitutively active IKK2 in astrocytes causes cerebellar atrophy and ataxia characterized by prominent Purkinje cell loss. a
Fast motor coordination is impaired in IKK2-CA mice at the age of 30-34 weeks. Latency to fall off an accelerating rotarod is reduced. Mean values
+/- s.e.m.; statistical analysis: 2-way-ANOVA (n = 11–15), p < 0.0001. b Impaired balance/movement precision in IKK2-CA mice at 30–34 weeks as
determined by time required to cross a narrow beam, diameter 11/17/28 mm. mean values +/- s.e.m.; statistical analysis: 2-tailed unpaired t-test
(n = 11–15), ** p < 0.01; *** p < 0.001. c IKK2-CA expression results in macroscopic cerebellar atrophy at 36 weeks. Scale bar: 1 mm. d Cerebellar
atrophy at 50 weeks shown by MRI (sagittal T2*-weighed image at the midline). Arrow: enlarged CSF filled ventricular cavity due to the reduced
cerebellar volume. Scale bar: 1 mm. e Variable onset of cerebellar atrophy between 12 and 20 weeks of age and further progression until the age
of 82 weeks. Diagram shows maximal rostro-caudal length of the cerebellum (single animals and mean); statistical analysis: 2-tailed Mann-Whitney-test,
* p < 0.05; ** p < 0.01; *** p < 0.001. f Histological analysis of the simple lobule reveals loss of Purkinje cells in the IKK2-CA model. Arrowhead: cells in
meningeal foldings, arrows: Purkinje cells. Scale bars: 100 μm (left panels); 20 μm (enlargements, right panels). g Time course of Purkinje cell loss in the
simple lobule. Quantification from Nissl stainings. Statistical analysis: 2-tailed unpaired t-test, *** p < 0.001, other time points p > 0.05. h Purkinje cell loss
in the simple lobule (SL) and the paramedian lobule (PML) at 36 weeks of age; statistical analysis: 2-tailed unpaired t-test (n = 6–8), *** p < 0.001
Lattke et al. Molecular Neurodegeneration  (2017) 12:16 Page 3 of 20
Fig. 2 (See legend on next page.)
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However, a prominent increase in CD45 immunoreactivity
was detected from 12 weeks (Fig. 2b) up to at least
36 weeks of age (Fig. 2c), indicating persistent neuroin-
flammation. The myeloid marker CD11b (Fig. 2d) and the
macrophage/microglia marker Mac-2 (Additional file 1:
Figure S2A) revealed a prominent increase in immunore-
activity, mainly of cells of arborized/ramified microglial
morphology, indicating strong microgliosis. We did not
observe any infiltration of B-cells by B220 and CD19
staining (data not shown) but could detect limited num-
bers of CD4- and CD8-positive T-cells (Fig. 2e and Add-
itional file 1: Figure S2B).
The subsequent characterization of the inflammatory
gene expression profile demonstrated that already at the
age of 8 weeks, before detectable immune cell infiltra-
tion, astrocyte-specific IKK2 activation is sufficient to
initiate a gene expression pattern correlating with the
observed innate immune response (microgliosis) and
adaptive immune cell recruitment (T-cell infiltration).
Similar to the profile identified at early postnatal devel-
opment and in primary astrocytes [14] we found diverse
NF-κB target genes upregulated, including chemokines
and cell adhesion molecules, which are involved in im-
mune cell recruitment, specifically MCP-1, Rantes,
Icam-1, Madcam-1 (Fig. 2f and g), as well as the cyto-
kines IL-1β and IL-6 (Fig. 2h) implicated in their activa-
tion. Also indicative of immune cell activation, immune
effector genes were induced, such as MHC class II pro-
teins and complement, specifically CD74, H2-Aa, C3,
C4b (Additional file 1: Figure S2C and D) and the acute
phase response factor and NF-κB target gene Lcn2
(Fig. 2i). Expression of these factors further increased to-
wards a late stage of cerebellar degeneration (Fig. 2f-i;
Additional file 1: Figure S2C and D). Expression of Lcn2
protein from 10 weeks onwards was accompanied by up-
regulation of GFAP and Mac2 as markers of astrogliosis
and microgliosis (Fig. 2j). These data show that 6–8
weeks after doxycycline withdrawal, when IKK2-CA
transgene expression reaches its full extent (Fig. 2j), a
full-blown neuroinflammatory response is elicited in the
cerebellum of IKK2-CA mice.
Remarkably, prominent infiltration of CD45 positive
cells is also found in various other brain regions (Add-
itional file 1: Figure S3A-D), demonstrating that IKK2-
mediated neuroinflammation is not restricted to the
cerebellum. However, even after long-term IKK2 activa-
tion, at 36 weeks of age, no neurodegeneration is detected
in other brain regions. Nissl staining does not reveal any
obvious atrophy or cell loss in any brain region beside the
cerebellum (Additional file 1: Figure S3E), and the quanti-
fication of NeuN positive neurons in the medulla oblon-
gata, another region with prominent neuroinflammation
(Additional file 1: Figure S3D), does not indicate any neur-
onal loss (Additional file 1: Figure S3F and G).
These data show that genetic IKK2 activation in astro-
cytes induces global neuroinflammation, likely by the in-
duction of various proinflammatory factors, in line with
its function as central activator of the NF-κB signalling
pathway. However, neurodegeneration is restricted to
the cerebellum, primarily to Purkinje cells, indicating a
selective vulnerability of Purkinje cells to neuroinflam-
mation and astroglial IKK2 activation.
Purkinje cell loss progresses independent of IKK2
activation and neuroinflammation after onset of ataxia
We next asked whether neurodegeneration depends on
continuous IKK2 activation and chronic neuroinflamma-
tion or whether it follows a hit-and-run mechanism. For
this purpose, we inactivated IKK2-CA expression by ad-
ministration of doxycycline in two experimental settings
(Fig. 3a), either at the pre-symptomatic stage (8 weeks of
age), or early after the onset of ataxia and inflammation,
but before substantial Purkinje cell loss (12 weeks of
age). Animals with continuous IKK2-CA expression
starting at 4 weeks of age show prominent inflammation
and astrogliosis at 20 weeks of age, indicated by Lcn2,
Mac2 and GFAP expression, respectively (Fig. 3b) that
correlates with prominent Purkinje cell loss (Fig. 3c and
e). In contrast, when transgene expression is inactivated
at 8 weeks, animals show neither Purkinje cell loss
(Fig. 3c and e) nor elevated levels of Lcn2, Mac2 or
GFAP (Fig. 3b). Notably, when transgene expression was
(See figure on previous page.)
Fig. 2 IKK2-CA animals exhibit prominent cerebellar neuroinflammation including microgliosis and astrogliosis. a-c Activation/infiltration of CD45
positive immune cells at different ages (8–36 weeks) in the cerebellum of IKK2-CA animals. d Staining for the myeloid cell marker CD11b indicates
massive microgliosis at 12 weeks of age. Higher magnification (right panels): microglia display arborized morphology; highly activated
microglia/infiltrated macrophages are rounded (amoeboid) cells. e Infiltration of Th-cells, shown by CD4 staining (age 12 weeks); right
panels: higher magnification. f-i IKK2-CA induces a proinflammatory gene expression profile in the cerebellum of IKK2-CA mice increasing
with age (qRT-PCR). Expression of chemokines (f), cell adhesion molecules (g), inflammatory cytokines (h) and the acute phase response
factor Lcn2 (i) is elevated in IKK2-CA mice. Expression levels presented relative to HPRT (mean +/- s.e.m.); statistical analysis: 2-tailed Mann-Whitney-test
(n = 4–7), ns: not significant (p > 0.05); * p < 0.05; ** p < 0.01. j Immunoblotting for Mac2 and GFAP indicates microgliosis and astrogliosis respectively,
transgene expression (IKK1/2 immunoreactivity) and induction of the NF-κB target Lcn2. Representative immunoblot and quantification of
GFAP immunoreactivity normalized to ERK2 (loading control), shown as mean +/- s.e.m. relative to Co 10w, statistical analysis: 2-tailed unpaired t-test
(n = 3–4), ns: not significant; * p < 0.05; ** p < 0.01; *** p < 0.001. Images (a-e) show DAPI co-staining. Scale bars: (a-c) 100 μm; (d-e) 100 μm, right
panels 25 μm
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inactivated at 12 weeks, Purkinje cell loss continued des-
pite normalized levels of Lcn2 and Mac2 and an arrest
of astrogliosis indicated by GFAP immunoreactivity
(Fig. 3b, d and e). Importantly, this continuing Purkinje
cell degeneration is likely not due to a slow transgene in-
activation or delayed resolution of inflammation, as
already 2 weeks after doxycycline re-administration (Dox
12w-14w, Additional file 1: Figure S4A) transgene, Lcn2
and Mac2 expression is almost undetectable (Additional
file 1: Figure S4B and C). In contrast, GFAP levels indi-
cative for astrogliosis remain elevated (Additional file 1:
Figure S4B and C). Furthermore, various IKK2-CA-
induced inflammatory mediators, including the major
proinflammatory cytokines TNFα, IL-1β, Rantes (CCL5)
Fig. 3 IKK2-CA inactivation after onset of ataxia abrogates neuroinflammation and arrests astrogliosis, but cannot prevent Purkinje cell loss. a
Schedule of doxycycline treatment to turn off IKK2-CA expression at different stages of phenotype development. No Dox: continuous expression
starting at 4 weeks of age, Inactivation of expression before onset of ataxia (Dox 8–20 weeks) or before onset of substantial Purkinje cell loss (Dox 12–
20 weeks). b Immunoblotting for Mac-2 and GFAP, indicating microgliosis and astrogliosis. Lcn2 indicates NF-κB activation, IKK1/2 immunoreactivity
IKK2-CA expression. Representative immunoblot and quantification of GFAP immunoreactivity normalized to ERK2 (loading control), shown as mean
+/- s.e.m. relative to Co 12w (n = 3–4). c-e Purkinje cell loss at 20 weeks (compared to controls) is prevented by early repression of IKK2-CA at 8 weeks
(c), but not by repression at 12 weeks of age (d). Representative Nissl staining (c, d) and quantification (e) is depicted. Values of untreated animals are
also presented in Fig. 1e. Scale bars 50 μm. Statistical analysis (b, e): 1-way ANOVA with Tukey’s post-test, * p < 0.05; ** p < 0.01; *** p < 0.001
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and IL-6, have returned close to control levels (Add-
itional file 1: Figure S4D), with the exception of MCP-1
(CCL2) and Icam-1 (Additional file 1: Figure S4E), indi-
cating that neuroinflammation is already largely resolved
at this early time point. Together these results demon-
strate that IKK2 activation in astrocytes for a limited
time interval is able to trigger Purkinje cell degeneration,
which after this initial hit becomes independent of IKK2
activation and neuroinflammation.
Purkinje cell loss is caused by irreversible Bergmann glia
dysfunction
The Bergmann glia is a specialized radial glia-like astro-
cyte subtype in the cerebellar cortex, which displays a
unique interaction with Purkinje cells. The cell bodies of
Bergmann glia are located in the Purkinje cell layer and
extend radially arranged Bergmann glia fibres that en-
wrap synapses on Purkinje cell dendrites. This tight as-
sociation is important for Purkinje cell survival [17–20]
and we asked whether astroglial IKK2 activation disrupts
this interaction and thereby induces the prominent
Purkinje cell degeneration.
We could confirm that the IKK2-CA transgene is
expressed in Bergmann glia, but not in Purkinje cells
and microglia by co-staining analyses using an antibody
recognizing only the human IKK2 derived transgene to-
gether with the astrocyte marker Aldh1l1 (Fig. 4a), the
Purkinje cell marker Calbindin (Additional file 1: Figure
S5A) or the microglia marker Iba1 (Additional file 1:
Figure S5B). There were a few IKK2-CA mice that do
not display obvious degeneration at the age of 20 weeks.
These mice show only week occasional IKK2-CA trans-
gene expression in Bergmann glia and an Aldh1l1 stain-
ing pattern similar to controls (Fig. 4a, early deg). In
animals of the same age, but with prominently degener-
ated cerebella, strong transgene and Aldh1l1 expression
was found mainly in the molecular layer (Fig. 4a, late
deg). This indicates that Purkinje cell loss is associated
with a distortion of Bergmann glia structure driven by
IKK2-CA. Quantitative analysis of the subcellular local-
isation of the NF-κB subunit RelA in IKK2-CA express-
ing Bergmann glia by co-immunostaining for RelA and
the transgene revealed a prominent increase in nuclear
localization of RelA (Fig. 4b-d), demonstrating NF-κB
activation in these cells.
The extent of structural alterations of Bergmann glia
was confirmed by GFAP staining. In pre-symptomatic
cerebella low GFAP containing parallel fibres crossed the
molecular layer similar to controls (Fig. 4e). In contrast,
Bergmann glia processes in the molecular layer were
thicker, disorganized, and more intensely stained in
degenerated cerebella (Fig. 4e), indicating astrogliosis-
like activation of the Bergmann glia. Interestingly, in
IKK2-CA cerebella without obvious degeneration,
occasionally individual Bergmann glia could be detected
that showed increased expression of GFAP and moder-
ate disorganization (Fig. 4f ), suggesting that Bergmann
glia activation might precede Purkinje cell loss.
Given that permanent IKK2 activation in astrocytes is
not required for progression of degeneration, Purkinje
cell loss could be driven by an early hit resulting in irre-
versible Bergmann glia dysfunction followed by delayed
Purkinje cell loss as a consequence. In this scenario,
Purkinje cell loss should only occur in areas with acti-
vated Bergmann glia. Therefore, repression of IKK2-CA
from 12 weeks of age would arrest further Bergmann
glia activation, but Purkinje cell loss could further con-
tinue in areas where previously Bergmann glia have been
activated, thereby explaining progression of degeneration
after block of transgene expression.
Alternatively, Purkinje cell loss could be triggered by
astrocyte-mediated early Purkinje cell damage (e.g. via
neurotoxic factors released by astrocytes) before
12 weeks of age. Here, Bergmann glia activation takes
place as a local secondary event caused by neuronal de-
generation. In this scenario, areas with Purkinje cell loss
would not necessarily show Bergmann glia activation,
and the pattern of Purkinje cell loss and Bergmann glia
activation would be independent of IKK2-CA inactiva-
tion starting at 12 weeks of age.
To determine whether Purkinje cell loss is cause or
consequence of Bergmann glia activation, we analysed
the local correlation of Bergmann glia activation and
Purkinje cell loss by GFAP/Calbindin co-staining
(Fig. 5). We quantified the GFAP-positive area frac-
tion in the molecular layer, as a measure of
Bergmann glia activation, as well as Purkinje cell
density in multiple fields and animals per experimen-
tal group (Fig. 5c and d). This analysis revealed that
activation of Bergmann glia was arrested, but not
reverted by transgene inactivation in line with the ar-
rest of GFAP induction (see Fig. 3b and Additional
file 1: Figure S4B), showing that Bergmann glia acti-
vation is irreversibly induced by transient IKK2 acti-
vation and thereby could trigger Purkinje cell loss
independent of transgene repression (Fig. 5c and d).
Supporting this model of Bergmann glia-driven
Purkinje cell degeneration, we found degeneration ex-
clusively in areas with activated Bergmann glia (Fig. 5a
and c). Importantly, IKK2-CA repression did not pre-
vent progression of Purkinje cell loss in areas with
activated Bergmann glia (Fig. 5b-d). Virtually all areas
with activated Bergmann glia displayed prominent
Purkinje cell loss at 20 weeks although transgene ex-
pression was inactivated in the period of 12 to
20 weeks of age (Fig. 5b-d). This shows that Purkinje
neurons are unable to survive for an extended time
period in an environment of activated Bergmann glia.
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Consistent with this model, in animals with continu-
ous transgene expression some areas show Bergmann
glia activation, but no or only moderate Purkinje cell
loss (Fig. 5a and c-d), indicating that Bergmann glia in
these areas have been activated only recently, and there-
fore the resulting delayed Purkinje cell loss is still in
Fig. 4 IKK2-CA expression in Bergmann glia disrupts their morphology in correlation with the stage of cerebellar degeneration. a Co-staining for
hIKK2 (transgene) and the astrocyte marker Aldh1l1 at 20 weeks of age in a cerebellum without detectable degeneration (“early deg”) and in a
late stage of degeneration (“late deg”) Arrows: Bergmann glia cell bodies. b-d IKK2-CA-expressing (hIKK2 positive) Bergmann glia marked by arrows
display nuclear localization of RelA indicating active NF-κB signalling (b). Arrowheads: Purkinje cell bodies (hIKK2 negative). c Enlargement of the box in
B. d Quantification of nuclear RelA immunofluorescence intensity in cells in the Purkinje cell layer, including IKK2-CA (hIKK2) expressing Bergmann glia.
n = 360 cells of 3 control and n = 480 of 4 IKK2-CA animals. Statistical analysis: 1-way ANOVA with Tukey’s post-test, *** p < 0.001. e Staining for GFAP
at 20 weeks of age shows Bergmann glia processes in the molecular layer. Controls and IKK2-CA cerebella without detectable degeneration (“early
deg”) show parallel Bergmann glia processes with weak GFAP. Severely degenerated cerebella (“late deg”) show intensely stained, thickened and
unorganized processes. f Occasionally, IKK2-CA animals without obvious Purkinje cell loss (age 12 weeks) show patches of Bergmann glia
with increased GFAP expression and first signs of disorganisation. Merged images show DAPI co-staining (blue). Scale bars: 20 μm
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progress. Similarly, 2 weeks after transgene inactivation
at 12 weeks of age, when inflammatory parameters are
largely normalized (Additional file 1: Figure S4), most
areas with Bergmann glia activation do not display
prominent Purkinje cell degeneration yet (Fig. 5c and d).
This indicates that Purkinje cell degeneration is a de-
layed process, which continues as a consequence of
Bergmann glia dysfunction between 14 and 20 weeks
(Fig. 5c and d).
To test the contribution of astrocyte-mediated microglia
recruitment/activation on neurodegeneration, we per-
formed a similar local correlation analysis of Purkinje cell
degeneration and microglia activation by Iba1/Calbindin
co-staining (Additional file 1: Figure S6A). This revealed
that local microgliosis increases between 12 and 20 weeks
if IKK2-CA is expressed whereas if the transgene is inacti-
vated at 12 weeks, local microgliosis is almost fully
reverted after 2 weeks (Dox12-14w, Additional file 1: Fig-
ure S6B and C), although mild residual microgliosis seems
to remain even at the age of 20 weeks (Dox12-20w; Add-
itional file 1: Figure S6B and C). Overall these findings
confirm that microgliosis is almost fully reversible.
Remarkably, Purkinje cell degeneration is not signifi-
cantly different between areas with and without micro-
gliosis, even in the animals with active IKK2-CA and
strong microgliosis (Additional file 1: Figure S6B and D),
indicating that microglia activation, in contrast to
Bergmann glia activation (Fig. 5), is not required for the
progression of Purkinje cell degeneration.
Importantly, we found that the phenotype of
GFAP.tTA/tetO.IKK2-CA mice is recapitulated also in a
newly established, independent mouse model named
Sept4-Cre/Rosa26-CAG-LSL-IKK2CA-IRESeGFP (short
IKK2-CASept4). In this system, Sept4-Cre mediated re-
combination induces expression of IKK2-CA and a GFP
reporter (Additional file 1: Figure S7A) specifically in
Bergmann glia (Fig. 6a), but not in Purkinje cells (Add-
itional file 1: Figure S7B), cerebellar granule neurons
(Additional file 1: Figure S7C), microglia (Additional file
1: Figure S7D), and other astrocytes beside Bergmann
glia, as shown for the cortex and corpus callosum (Add-
itional file 1: Figure S7E). Similar to the doxycycline-
driven pan-astrocyte expression of IKK2-CA, this results
in astrogliosis-like alterations of Bergmann glia morph-
ology with GFAP upregulation (Fig. 6a and b), and the
upregulation of the NF-κB target gene Lcn2 (Fig. 6c).
Also microgliosis is present in the cerebellum of the
IKK2-CASept4 mice, shown by induction of the macro-
phage/microglia marker Mac2 (Fig. 6c) and immunos-
tainings for Iba1 (Additional file 1: Figure S7D)
Importantly, also IKK2-CASept4 animals display an atro-
phy of the cerebellum (Fig. 6d and e) and a loss of
Purkinje cells (Fig. 6f and g). Although the phenotype
develops later and is less pronounced than in the
GFAP.tTA/tetO.IKK2-CA model, possibly due to re-
duced or delayed transgene expression, these findings
overall confirm the critical role of IKK2 activation in
Bergmann glia in the induction of Purkinje cell
degeneration.
Downregulation of astroglial glutamate transporters
coincides with dark cell degeneration indicating
excitotoxic neurodegeneration
We next asked how Bergmann glia activation might
drive Purkinje cell loss. Beside the disruption of the
structural support due to morphological alterations,
Bergmann glia activation might also result in the pro-
duction or impaired clearance of neurotoxic factors. One
such putative neurotoxic factor is the NF-κB target gene
Lcn2, which is secreted by astrocytes and is highly up-
regulated in the cerebellum of both the IKK2-CA and
IKK2-CASept4 mice (Figs. 2i, j and 6c). Lcn2 was shown
(See figure on previous page.)
Fig. 5 Local IKK2-CA-induced Bergmann glia activation drives subsequent Purkinje cell loss. a, b Variable loss of Purkinje cells (calbindin-positive) in
areas with astrogliosis-like Bergmann glia activation (increased GFAP staining) in IKK2-CA animals at 20 weeks. Areas without detectable degeneration
(“early deg”) showing parallel Bergmann glia processes and degenerated areas (“late deg”) are depicted (a). After IKK2-CA repression by doxycycline
from 12 weeks of age severe Purkinje cell loss at 20 weeks is evident in areas with Bergmann glia activation, but not in fields with normal Bergmann
glia (b). Inlays: higher magnification of GFAP channel in the molecular layer. DAPI co-staining (blue). Scale bars 50 μm (inlays 20 μm). c, d Quantitative
analysis of the spatial correlation of Bergmann glia activation (>8% area GFAP+ in the molecular layer) and Purkinje cell degeneration (<15 Purkinje
cells/mm) in individual microscopic fields. Degeneration is almost exclusively found in fields with activated Bergmann glia (c). Bergmann glia activation
increases between 12 and 20 weeks in IKK2-CA expressing animals, but is arrested by doxycycline (C/D). Fields with activated Bergmann glia display
variable Purkinje cell loss at 20 weeks in animals expressing IKK2-CA, whereas after treatment with doxycycline from 12 to 20 weeks, most fields with
activated Bergmann glia show prominent Purkinje cell loss (C/D). Purkinje cell loss progresses between 2 weeks (Dox 12-14w) and 8 weeks (Dox 12-
20w) after doxycycline application in fields with Bergmann glia activation. c Bergmann glia activation and Purkinje cell numbers in individual fields. Red
numbers: percentage of fields in the specific quadrant. Analysis of 6 fields/animal with n = 4/6/9/7/6 animals for Co/IKK2-CA12w/20w/Dox 12-14w/Dox
12-20w. d Percentage and absolute numbers of fields with activated Bergmann glia (green) and Purkinje cell loss (grey) from Co and IKK2-CA mice at
the age of 12, 14 and 20 weeks (12w, Dox 12-14w, 20w) are shown. Numbers represent fields with activated Bergmann glia vs. total fields analysed (left
panel) and fields with degenerated Purkinje cells and activated Bergmann glia vs. total fields with activated Bergmann glia (right panel). Transgene
inactivation via doxycycline application at the age of 12 weeks (Dox 12-20w) stops the increase in Bergmann glia activation compared to
animals at 12 w (left panel), but does not stop Purkinje cell loss (right panel). Statistical analysis: Fisher’s exact test, ns: not significant (p >
0.05); ** p < 0.01; *** p < 0.001
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to be neurotoxic in vitro, and to critically contribute to
the pathogenesis of CNS disorders in animal models
[21–23]. In vitro studies also proposed Lcn2 as an
important mediator of astrogliosis and microgliosis
[24–27]. However, Lcn2 deficiency in IKK2-CA ani-
mals did affect neither cerebellar atrophy (Fig. 7a)
nor Purkinje cell loss (Fig. 7b and c). Surprisingly,
astrogliosis and microgliosis were also not altered by
the lack of Lcn2, as depicted by immunoblotting for
GFAP and Mac2 (Fig. 7d). This demonstrates that
Lcn2 does not contribute to neuropathology in our
model of inflammatory Purkinje cell degeneration.
Fig. 6 Bergmann glia specific IKK2-CA expression in the IKK2-CASept4 model recapitulates the cerebellar pathology of the GFAP.tTA/tetO.IKK2-CA mice.
a Co-Immunostaining for the GFP reporter coexpressed with the IKK2-CA transgene and for Aldh1l1 as astrocyte marker shows co-localisation. Arrows
indicate Bergmann glia cell bodies. Scale bar: 20 μm. b Immunostaining for GFAP shows intensly stained and unorganized Bergmann glia processes in
the molecular layer indicating Bergmann glia activation in IKK2-CASept4 mice. Inlays: higher magnification of the GFAP channel in the molecular layer.
Scale bars: 20 μm. c Immunoblotting for Mac2 indicates microgliosis, transgene expression (IKK 1/2 immunoreactivity) and induction of
the NF-κB target Lcn2. d Sept4-Cre induced IKK2-CA expression results in macroscopic cerebellar atrophy at 28–29 weeks. Scale bar:
1 mm. e Quantification of maximal rostro-causal length of the cerebellum (single animals and mean); statistical analysis: 2-tailed unpaired
t-test, *** p < 0.001. f Histological analysis of the simple lobule reveals loss of Purkinje cells in the IKK2-CASept4 model. Arrows: Purkinje
cells. Scale bars: 100 μm (left panels); 20 μm (enlargements, right panels). g Quantification of Purkinje cell loss from Nissl stainings. Statistical analysis:
2-tailed unpaired t-test, * p < 0.05
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Another well-known factor implicated in neurodegen-
eration is the neurotransmitter glutamate. Several stud-
ies attributed Purkinje cell loss to excitotoxicity as
consequence of downregulation of the glutamate trans-
porters EAAT1 and EAAT2 in Bergmann glia, resulting
in impaired clearance of extracellular glutamate [17–19].
Notably, in GFAP/IKK2-CA animals we found a pro-
nounced downregulation of EAAT1 and EAAT2 already
at 10 weeks (Fig. 8a) correlating with transgene expres-
sion (Fig. 2j) and in line with a potential pathogenic role
in ataxia and Purkinje cell loss. Accordingly, we ob-
served downregulation of EAAT1 and EAAT2 also in
the IKK2-CASept4 model (Additional file 1: Figure S8A).
In addition, we identified a pronounced reduction of the
AMPA receptor subunit GluR1 in GFAP/IKK2-CA mice,
indicating additional alterations in glutamatergic signalling
(Fig. 8a). Interestingly, downregulation of EAAT1, EAAT2
and GluR1 is fully reversible upon IKK2-CA transgene
inactivation at 20 weeks of age (Fig. 8b and c). EAAT2
levels are already normalized after 2 weeks of doxycycline
application (Additional file 1: Figure S8B). This finding in-
dicates that continuous glutamate transporter downregu-
lation of EAAT1 and EAAT2 is not required for the
progression of Purkinje cell loss, as transgene repression
from 12 weeks of age can reconstitute EAAT1/2 and
GluR1 expression, but cannot prevent Purkinje cell loss.
However, transgene inactivation at 8 weeks, a time point
at which no obvious changes in EAAT1/2 expression are
seen (see Fig. 3) prevented Purkinje cell degeneration. Re-
markably, downregulation of EAAT2 is not seen through-
out the brain (Additional file 1: Figure S8C and D) but is
rather restricted to the cerebellum and to a lesser extent
also observed in the medulla (Additional file 1: Figure S8E
and F). This may argue for a cell-type specific effect of
IKK2 mediated EAAT1/2 regulation in a subset of astro-
cytes, most notably in Bergmann glia.
Fig. 7 Lcn2 does not contribute to Purkinje cell loss, astrogliosis and microgliosis in IKK2-CA mice. a Cerebellar atrophy at 20 weeks of
age. Measurement of maximal rostro-caudal length of the cerebellum (single animals and mean). Statistical analysis: 1-way-ANOVA, ns: not
significant (p > 0.05); *** p < 0.001. b, c Loss of Purkinje cells (arrows) at 20 weeks. Nissl-stained images (b) and quantification in the simple
lobule (c). Scale bars: 25 μm. Statistical analysis: 1-way-ANOVA, ns: not significant (p > 0.05); ** p < 0.01; *** p < 0.001. d Astrogliosis, microgliosis and
IKK2-CA expression indicated by GFAP, Mac2 and IKK1/2. ERK2 is detected as loading control
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Fig. 8 (See legend on next page.)
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In contrast to the glial glutamate transporters, expres-
sion of EAAT4, a glutamate transporter expressed spe-
cifically by Purkinje cells [28] is only slightly reduced at
the age of 10 and 12 weeks (Fig. 8a), excluding a major
loss of Purkinje cells as well as compensatory induction
of EAAT4 at this early stages. Furthermore, at a later
stage (age 36 weeks), we could not detect compensatory
induction of the neuronal glutamate transporters EAAT3
and EAAT4 in the cerebellum (Additional file 1: Figure
S8G). Instead, EAAT4 expression was prominently de-
creased, well correlating with the massive loss of
Purkinje neurons at this time point. In addition, reduc-
tion in EAAT3 levels also suggested loss of other neur-
onal cells in the cerebellum in addition to Purkinje
neurons (Additional file 1: Figure S8G).
EAAT1 and EAAT2 have been described as genes that
can be directly suppressed by NF-κB in specific condi-
tions [29, 30]. However, unexpectedly, EAAT1/2 mRNA
levels are not altered in IKK2-CA animals (Additional
file 1: Figure S8H), demonstrating that downregulation
of these transporters is not caused by direct IKK2/NF-
κB mediated transcriptional repression, but is rather due
to a posttranscriptional mechanism, regulating EAAT1/2
translation or protein stability. Interestingly, in silico
analysis of EAAT1/2 mRNA sequences using the online
tool TargetScanMouse 7.1 identified several putative
binding sites for the NF-κB regulated miRNA miR-146a,
which is highly upregulated in the IKK2-CA animals
(Additional file 1: Figure S8I). Therefore, miRNA medi-
ated translational inhibition via NF-κB regulated miR-146a
represents a potential mechanism for downregulation of
EAAT1/2 protein levels in IKK2-CA mice, an issue, which
needs detailed analysis in the future.
Supporting the hypothesis that excitotoxicity is in-
volved in the initiation of neurodegeneration, we found
reduced expression of the postsynaptic density protein
Prosap1/Shank2 already at the age of 10 weeks in the
cerebellum, whereas VGAT expression as a marker of
the axonal/presynaptic compartment of the GABAergic
Purkinje neurons was only marginally altered (Fig. 8d
and e). As excitotoxicity is a consequence of local hyper-
excitation of individual synapses, the postsynaptic/
dendritic compartment might display an early damage
before other parts of Purkinje cells get affected. Finally,
we found ultrastructural alterations described as dark
cell degeneration, which have been shown to occur in
Purkinje cells dying by excitotoxicity. Dark cell degener-
ation is characterized by a darkened cytoplasm, dilated
Golgi cisternae, and a dilated endoplasmatic reticulum
[18, 31]. At 16 weeks, we could detect such alterations
in 48% of analysed Purkinje cells in IKK2-CA animals
but never in controls (Fig. 8f and g).
Discussion
In the present study, we demonstrate that genetic activa-
tion of IKK2 in astrocytes and especially in Bergmann
glia results in chronic neuroinflammation and subse-
quent cerebellar ataxia with a rather selective degener-
ation of Purkinje neurons in adult mice. Degeneration is
caused via a non-cell-autonomous mechanism disrupt-
ing the essential local Bergmann glia Purkinje cell inter-
action. Importantly, only a restricted time period of
neuroinflammation is sufficient to initiate subsequent
degeneration of Purkinje neurons. In addition, we show
that inflammation-associated astrogliosis induced by
IKK2 activation results in a strong downregulation of
the glial glutamate transporters EAAT1 and EAAT2 in
the cerebellum, most likely leading to a local imbalance
of glutamate homeostasis and promoting excitotoxicity.
Chronic neuroinflammation is increasingly recognized
as a pathogenic mechanism in neurological disorders, es-
pecially in neurodegeneration [2]. Remarkably, distinct
neuronal populations show different degrees of vulner-
ability to neurodegeneration, a phenomenon that is not
well understood. This selective vulnerability is usually at-
tributed to cell intrinsic properties of the affected neu-
rons, although interactions with glial cells and local
inflammatory conditions also might play a role [32].
Interestingly, depending on the experimental setup, in-
flammation alone can be sufficient to induce degener-
ation of vulnerable neurons. In a model of LPS-induced
chronic neuroinflammation, degeneration of dopamin-
ergic neurons was detected [33], whereas in the IKK2-
CA model the survival of dopaminergic neurons is not
(See figure on previous page.)
Fig. 8 Reversible downregulation of glutamate transporters and GluR1 by IKK2-CA is associated with signs of synaptic degeneration and dark cell
degeneration of Purkinje cells. a Downregulation of glial glutamate transporters EAAT1/2 and the AMPA-receptor subunit GluR1 by IKK2-CA. The
Purkinje cell specific glutamate transporter EAAT4 is only moderately reduced. Re-probed membranes shown also in Fig. 2j (same ERK2 loading
control). b, c Repression of IKK2-CA restores expression of EAAT1, EAAT2, and GluR1. Re-probed membranes shown also in Fig. 3b (same ERK2
loading control). Representative immunoblot (b) and quantification (c). Values normalized to ERK2, shown as mean +/- s.e.m. relative to Co 12w
(n = 3–4). d, e Levels of the postsynaptic density protein Prosap1 are reduced, whereas there is no major change in the presynaptic protein VGAT.
Immunoblot (d) with quantification (e). mean values +/- s.e.m. relative to Co 10w, normalized to ERK2 (loading control), statistical analysis: 2-tailed
unpaired t-test (n = 3–4), ns: not significant; * p < 0.05. f-g Ultrastructural analysis shows darks cell degeneration of Purkinje cells in IKK2-CA animals
(age 16 weeks) with darkened cytoplasm, irregular morphology and the dilatation of Golgi cisternae (arrowheads) and endoplasmatic reticulum
(arrows). Scale bars: 2 μm (upper panels), 1 μm (lower panels). g Quantification of n = 60 Purkinje cells of controls and n = 48 Purkinje cells of IKK2-
CA animals (pooled of each 3 animals); statistical analysis: Fisher’s exact test, p < 0.0001
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affected, despite global chronic neuroinflammation
[15]. Instead we found a selective degeneration of
Purkinje neurons, which is a pathological hallmark of
inflammatory cerebellar ataxias. In these neurodegen-
erative disorders, a variety of strong neuroinflamma-
tory insults, e.g. autoimmune disorders like
paraneoplastic syndromes, converge on a selective de-
generation of Purkinje cells [34–36].
Our study supports a comprehensive model how di-
verse inflammatory insults could cause cerebellar ataxia:
Disease-mediated elevation of danger signals like TLR li-
gands and inflammatory cytokines in the cerebellum is
able to activate IKK2 signalling in astrocytes [2, 3],
which as a consequence triggers astrogliosis-like activa-
tion of Bergmann glia and subsequent Purkinje cell loss.
In favour of this hypothesis, genetic inactivation of
Myd88, a critical signal transduction component in TLR
signalling and important for downstream IKK/NF-κB ac-
tivation, alters neuroinflammation and attenuates
Purkinje cell loss in a spinocerebellar ataxia type 6
mouse model [37]. Several studies indicate that the path-
ology of inflammatory cerebellar ataxia is very similar to
the one observed in the IKK2-CA model, importantly
also showing prominent astrogliosis including activation
of Bergmann glia [38–42].
With the detailed analysis of the local correlation of
Purkinje cell death and Bergmann glia activation to-
gether with our rescue approach and Bergmann glia spe-
cific IKK2 activation in IKK2-CASept4 mice we provide
strong evidence that such astrogliosis-like activation of
Bergmann glia is sufficient to trigger Purkinje cell degen-
eration and explains the selective vulnerability of
Purkinje cells to inflammatory insults. In contrast, our
experiments do not indicate a similar crucial role of
microglia activation in Purkinje cell degeneration. Over-
all these findings support the idea that IKK2-driven
Bergmann glia activation is able to cause Purkinje cell
loss in inflammatory cerebellar ataxias and suggest that
the IKK2-CA model can serve as a useful tool to study
these disorders. The detailed analysis of the IKK2-
CASept4 model also revealed that the Sept4-Cre driver
line, which was generated by the GENSAT project [43],
but was not thoroughly characterized, can be used to in-
duce Cre-mediated recombination selectively in Berg-
mann glia, thus providing a tool to study gene function
specifically in Bergmann glia without targeting other
astrocytes.
Most known functions of IKK2 in the regulation of in-
flammatory processes are linked to its function in NF-κB
signalling. In line with this, we found IKK2-CA mediated
NF-κB activation in Bergmann glia measured by nuclear
localisation of p65. In addition, our gene expression
analyses revealed the upregulation of several proinflam-
matory NF-κB target genes in the cerebellum upon
IKK2-CA expression and their immediate downregula-
tion upon doxycycline-mediated transgene inactivation.
However, it remains open so far and needs to be ad-
dressed in future studies, whether NF-κB signalling or
NF-κB-independent IKK2 phosphorylation substrates
like IRS1, Foxo3A, SNAP23 or TSC1 [44] are mediating
Bergmann glia activation and subsequent Purkinje cell
degeneration.
The results obtained with the conditional inactivation
of the transgene also revealed a surprising aspect,
namely that astrogliosis-like Bergmann glia activation is
irreversible and determines an early “point of no return”
resulting in inevitable Purkinje cell loss. The
phenomenon of such an early “point of no return” pre-
ceding actual neuron loss is observed in different neuro-
degenerative disorders, which complicates therapeutic
approaches [45]. Whereas this phenomenon is usually
attributed to cell intrinsic mechanisms of neurons, e.g.
synaptic dysfunction, our data show that it can also de-
pend on an irreversible astrocyte defect. Overall our data
implicate that early intervention is crucial for the devel-
opment of therapeutic strategies for treatment of inflam-
matory cerebellar ataxias.
The nature of the specific support functions of Berg-
mann glia required for Purkinje cell survival requires
further investigation. Beside loss of structural support,
activation of Bergmann glia might induce the production
of toxic substances or impair the clearance of such sub-
stances. In contrast to its pathogenic role in the parkin-
sonian dopaminergic system [46] and in other model
systems [21–23], we could exclude any contribution of
the secreted neurotoxic factor Lcn2 to Purkinje cell
degeneration.
In fact, our data indicate that impaired clearance of
glutamate via the glutamate transporters EAAT1 and
EAAT2 by Bergmann glia could be responsible for
Purkinje cell degeneration. Similar to our findings, other
studies [17–19] found a downregulation of these trans-
porters in astrocyte-mediated Purkinje cell degeneration
and indirect evidence for altered glutamate homeostasis.
A recent study shows hyperexcitability of Purkinje cells in
response to IL-1β mediated downregulation of EAAT1
and Bergmann glia activation in EAE [47]. As excitotoxi-
city is a consequence of neuronal hyperexcitation, these
findings support the hypothesis that inflammation-
associated impairment of glutamate uptake by Bergmann
glia causes Purkinje cell excitotoxicity.
Our finding that restoration of EAAT1/2 expression
after transgene inactivation at 12 weeks of age did not
prevent progression of Purkinje cell degeneration high-
light the notion that persistent excitotoxicity is not ne-
cessary to induce Purkinje cell death. In contrast, a
limited time period of deregulated glutamate homeosta-
sis is sufficient to cause this irreversible Purkinje cell
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damage. Furthermore, glutamate uptake could addition-
ally be compromised by dislocation of EAAT1/2 from
Purkinje cell synapses due to an activation-related re-
traction of Bergmann glia processes.
The reversible IKK2-dependent repression of EAAT1
and EAAT2 in vivo is also of broader relevance, as neuro-
inflammation and excitotoxicity are supposed to be in-
volved in the pathogenesis of various neurodegenerative
diseases, but the molecular link between both processes is
not well understood [48]. Interestingly, several IKK/NF-κB
activating cytokines can reduce glutamate transporter ex-
pression and glutamate uptake in astrocytes [48], although
cell culture studies produced conflicting results on the
role of NF-κB in EAAT1/2 regulation [29, 30, 49]. Our
data now clearly indicate that IKK2 in cerebellar astro-
cytes acts as negative regulator of EAAT1 and EAAT2
expression in vivo, remarkably not by direct NF-κB-
mediated transcriptional repression, but via a posttran-
scriptional mechanism, reducing EAAT1/2 protein levels
without affecting mRNA expression. While initial results
show an induction of miR-146a, a NF-κB inducible
miRNA, which is predicted to target both EAAT1 and
EAAT2 mRNAs and could thereby inhibit mRNA transla-
tion, other possible mechanisms need to be explored in
future studies, including the possibility of a NF-κB inde-
pendent regulation of EAAT1/2 protein stability by IKK2.
Overall, these findings revealed an unexpected aspect
of the regulation of glutamate homeostasis by the IKK2
system, suggesting a novel link between neuroinflamma-
tion and deregulation of glutamate homeostasis in CNS
disorders.
Conclusions
Our results implicate that inflammation-mediated dys-
function of a specific astrocyte population is sufficient to
determine the selective vulnerability of neurons to de-
generation, an aspect that so far receives only limited at-
tention. Importantly, this novel non-cell-autonomous
mechanism significantly improves the understanding
how diverse insults by inducing IKK2 activation and NF-





double transgenic mice named IKK2-CA or IKK2-DN
were described previously [14]. For IKK2-CA repression
doxycycline (0,5 g/l) was administered in the drinking
water of all mice from conception to 4 weeks of age and
as indicated in Fig. 3a and Additional file 1: Figure S4A.
Both male and female mice were included (no difference
in phenotype, data not shown), and similarly doxycycline
treated tetO.IKK2-CA or GFAP.tTA single transgenic
mice and wildtype littermates were used as controls (sin-
gle transgenic mice were indistinguishable from wild-
type, data not shown). To analyse the contribution of
Lcn2, the Lcn2 null allele Lcn2tm1Aade [50] was bred into
the GFAP/IKK2-CA line. Sept4-Cre mice (Tg(Sept4-
cre)OX54Gsat/Mmucd, MGI ID: MGI:5086169) were
generated by the GENSAT Project at Rockefeller Univer-
sity [43] and obtained by the ‘Mutant Mouse Resource
Research Centers’ (Gensat, RRID:MMRRC_036147-
UCD). Sept4-Cre mice are described to give rise to Cre-
mediated recombination in cerebellar glia cells (subtype,
Bergmann glia; http://www.gensat.org/), which was vali-
dated by co-staining analyses in this study (Fig. 6 and
Additional file 1: Figure S7). To generate Rosa26-CAG-
LSL-IKK2CA-IRESeGFP mice the targeting vector was
placed into the Rosa26 locus (Additional file 1: Figure
S7A) via electroporation of C57BL/6-derived embryonic
stem (ES) cells. Correctly targeted ES cells were selected
and chimeric animals were bred to C57BL/6 mice to
generate mutant mice. Sept4-Cre mice were crossed to
Rosa26-CAG-LSL-IKK2CA-IRESeGFP mice (Additional
file 1: Figure S7A) to generate double transgenic Sept4-
Cre/Rosa26-CAG-LSL-IKK2CA-IRESeGFP mice termed
IKK2-CASept4 in order to express IKK2-CA and eGFP in
Bergmann glia. All mice were of a pure C57BL/6 genetic
background. Both male and female mice were included
and single transgenic mice and wildtype littermates were
used as controls.
Rotarod and beam-walking test
Fast movement coordination was analysed with the
ENV-575 M rotarod (Med Associates Inc.). After 1 min
at 4 rpm for adjustment, the cylinder accelerated within
5 min to 40 rpm. The latency to fall was recorded. To
analyse motor learning, each animal was subjected to
the task 3 times per day for 4 consecutive days.
In the beam-walking test, the mice had to traverse a
narrow beam to escape from a small, elevated platform
to a closed dark box, with subtle encouragement by the
experimenter. Beginning from the second trial for each
trial the crossing time was recorded. For the first experi-
ment (Fig. 1) a protocol with 4 training trials per day for
3 days with a 12 mm square beam (length 80 cm) was
used. On the two following days, probe trials with differ-
ent beam sizes were done in duplicate. Other experi-
ments were performed with 4 consecutive trials on 1 day
with a 12 mm square beam.
High-resolution MRI
Experiments were carried out under isoflurane
anesthesia (5% for induction, 1.5% for maintanence,
mixed with air). All Data were acquired on a dedicated
small animal MRI system (BioSpec 117/16 USR, Bruker
Biospin, Ettlingen, Germany) applying a two-element
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cryogenically cooled transmit/receive surface coil. The
animals were positioned in prone position with the head
fixed to a purpose-built head holder and nose cone.
Body temperature was maintained at 37 °C using a water
heated animal bed. T2*-weighted images were acquired
applying a FLASH sequence with acquisition parameters
as: TR/TE = 190/5 ms, flip angle a = 17.5°, slice thickness
s = 0.5 mm, in-plane resolution Dr = 65 x 65 μm2. For
coverage of the entire cerebellum 18 slices without any
interslice gap were acquired in a total measurement time
TACQ = 10 min.
Protein isolation and immunoblotting
For tissue protein extracts brain regions were snap-
frozen in liquid nitrogen, grinded while frozen and lysed
in RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1%
Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS,
pH 7.4) supplemented with protease inhibitors (1 mM
PMSF and Roche “complete mini” -tablets). Non-lysed
debris was removed by centrifugation (25 min, 17000 g).
Equal amounts of protein (usually 20–50 μg) were sep-
erated by SDS-PAGE under reduced-denaturing condi-
tions. For an improved dissociation of glutamate
transporter oligomers, samples were usually denatured
with a twofold concentrated urea supplemented
Laemmli loading buffer (200 mM Tris-HCl, 15% gly-
cerol, 4% SDS, 6 M Urea, 5% β-mercaptoethanol). Pro-
teins were transferred to PVDF membranes and blocked
for 1 h with 5% dry milk in TBS buffer. Primary anti-
bodies were incubated in the blocking solution overnight
at 4 °C or for 2 h at room temperature, secondary anti-
bodies for 1 h at room temperature. Luminescence sig-
nals were detected with the “Intelligent Dark Box” (Fuji).
The membranes were usually reprobed several times
with different antibodies, including anti-ERK2 as loading
control.
RNA extraction, cDNA synthesis and qPCR
RNA was prepared with the Peqlab Trifast kit and cDNA
synthesized with the Roche Transcriptor High fidelitiy
cDNA synthesis kit with oligo-dT primers. Quantitative
Realtime-PCR (qPCR) assays designed with the Roche
“Universal Probe Library” system were run on the Roche
Lightcycler 480. Values were normalized to HPRT as
housekeeping gene. Intron spanning primers for qPCR
assays were designed with the online “Roche Universal
ProbeLibrary Assay Design Center” and used with the
respective fluorescent UPL probe in standard assay con-
ditions for the Roche Universal Probe qPCR system. Se-
quences are as follows:
HPRT1 (5’-gga gcg gta gca cct cct-3’, 5’-ctg gtt cat cat cgc
taa tca c-3’, UPL #69), MCP-1(5’-cat cca cgt gtt ggc tca-3’,
5’-gat cat ctt gct ggt gaa tga gt-3’, UPL #62), Rantes (5’-tgca
gaggactctgagacagc-3’, 5’-gagtggtgtccgagccata-3’, UPL #110),
IL-1β (5’-tgt aat gaa aga cgg cac acc-3’, 5’-tct tct ttg ggt att
gct tgg-3’, UPL #78), IL-6 (5’-gct acc aaa ctg gat ata atc agg
a-3’, 5’-cca ggt agc tat ggt act cca gaa-3’, UPL # 6), ICAM-1
(5’-ccc acg cta cct ctg ctc-3’, 5’-gat gga tac ctg agc atc acc-3’,
UPL #81), Madcam-1 (5’-gggcaggtgaccaatctgta-3’, 5’-atag
gacgacggtggagga-3’, UPL #72), Lcn2 (5’-ccatctatgagctacaaga
gaacaat-3’, 5’-tctgatccagtagcgacagc-3’, UPL #58), C3 (5’-
accttacctcggcaagtttct-3’, 5’-ttgtagagctgctggtcagg-3’, UPL
#76), C4b (5’-tctcacaaacccctcgacat-3’, 5’-agcatcctggaacacct-
gaa-3’, UPL #10), CD74 (5’-gccctagagagccagaaagg-3’, 5’-
tggtacaggaagtaagcagtgg-3’, UPL #21), H2-Aa (5’-tggaggtgaa
gacgacattg-3’, 5’-ctcatcaccatcaaattcaaatg-3’, UPL #80), TNF
(5’-tgcctatgtctc- agcctcttc-3’, 5’-gaggccatttgggaacttct-3’,
UPL #49).
For the analysis of miR-146a expression, total RNA
was prepared with the Qiagen “miRNeasy” kit and qPCR
performed with the Qiagen Quantitect primer assays for
miR-146a and RNU-2 as housekeeping gene.
Histology and immunofluorescence staining
Brains for histology were fixed by immersion with 4%
PFA (3-5 h or overnight at 4 °C), dehydrated and embed-
ded in paraffin. Coronal sections were prepared with a
thickness of 7 μm. After rehydration, heat mediated anti-
gen retrieval was performed with sodium citrate
(10 mM, pH 6, 0.05% Tween 20) or Tris-EDTA (10 mM
Tris, 1 mM EDTA, pH 9, 0.05% Tween 20). For full
permeabilization, sections were incubated with 0.5% Tri-
ton X-100 for 30 min. Sections were then washed with
PBS and blocked with 5% BSA in PBS for 1 h. Incuba-
tion with the primary antibodies (in 5% BSA) was per-
formed overnight at 4 °C, secondary antibodies (in 5%
BSA) were applied for 1 h at room temperature with
100–250 ng/ml DAPI for nuclear counterstaining.
Stainings for CD45, CD4, CD8, CD11b and Mac-2 were
performed with 10 μm kryosections from natively frozen
brains that were fixed with cold methanol (- 20 °C). Block-
ing and staining was performed as described above. The
directly PE-labeled rat anti-CD11b antibody was applied
for 2 h after careful washing after the secondary antibody,
or directly after blocking, when only directly labeled anti-
bodies were used.
Fluorescence images were acquired with the Zeiss
Axiovert 200 M microscope with filters for DAPI,
FITC/Alexa Fluor 488, DsRed/PE and TexasRed/Alexa
Fluor 568/594, with 5/10/20x objectives and the Zeiss
Axiovision software, except for Fig. 6a and b, Add-
itional file 1: Figures S3F and S7 where images were
aquired with the Keyence BZ-9000 (BIOREVO)
microscope and the BZ-II Viewer software. For each
channel, exposure times were separately adjusted and
kept for the complete session. Adjustment of contrast
and brightness was performed for each channel separ-
ately, but in all compared pictures equally.
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Quantification of the correlation of Bergmann glia or
microglia activation and Purkinje cell loss
For quantification of the correlation of Bergmann glia or
microglia activation and Purkinje cell loss, images of the
cerebellar molecular layer and the adjacent Purkinje cell
layer in GFAP/Calbindin or Iba1/Calbindin co-stainings
were acquired in one session with a 20x objective. For
quantification of Bergmann glia activation, a region of
interest encompassing the major area of the molecular
layer was defined, where the local GFAP positive area
fraction (area above a manually set threshold vs. total
area) was measured by ImageJ. For quantification of
microglia activation, a region of interest including the
major area of the molecular layer, Purkinje cell layer and
granule cell layer was defined, where the local Iba1 posi-
tive area fraction (area above a manually set threshold
vs. total area) was quantified. Then for the specific image
the number of Purkinje cells was counted and the length
of the Purkinje cell layer measured to calculate the local
Purkinje cell density.
Antibodies for immunoblotting and immunofluorescence
The following antibodies were used for immunoblotting:
Mouse anti-calbindin (Sigma), rabbit anti-EAAT2 (Cell
Signaling Technology), mouse anti-NeuN (Millipore),
Rabbit anti-GluR1 (Millipore), rabbit anti-EAAT4
(Abcam) and goat anti-Lcn2 (R&D Systems). Goat anti-
IKK2 (human specific, detects only the transgene), rabbit
anti-IKK1/2, rabbit anti-ERK2, rabbit anti-EAAT1, rabbit
anti-EAAT3, rabbit anti-galectin 3 (Mac-2), mouse anti-
GFAP and all corresponding HRP coupled secondary anti-
bodies were obtained from Santa Cruz Biotechnologies.
Rabbit anti-Prosap1 was kindly provided by Prof. To-
bias Böckers (Ulm, Germany).
Goat anti-IKK2, mouse anti-GFAP, mouse anti-NeuN
and mouse anti-calbindin were also used for immuno-
fluorescence. Additionally, following antibodies were
used for immunofluorescence: mouse anti-Aldh1l1
(Abcam), rabbit anti-RelA (Santa Cruz Biotechnologies),
PE-labeled rat anti-CD11b (eBioscience), and rat anti-
CD45, rat anti-CD8, rat anti CD4 (all from BD Biosci-
ences), rabbit anti-Iba1 (Wako) and chicken anti-GFP
(Abcam). Corresponding Alexa Fluor-conjugated sec-
ondary antibodies were obtained from Molecular Probes
(Life Technologies).
Electron microscopy
The protocol for the TEM studies on Purkinje cells was
adapted from the work of Custer et al. [18]. Mice were
anesthetized and transcardially perfused with PBS
followed by 4% PFA/0.5% glutaraldehyde and then by 2%
PFA/3% glutaraldehyde in PBS. After excision the whole
brain was postfixed for at least overnight by immersion
in 2% PFA/3% glutaraldehyde in PBS. The cerebella were
cut with a vibratome into 0.5 mm thick coronal sections.
Of these sections, pieces of the cerebellum containing
the simple lobule were dissected. Tissue pieces were
stained with osmium tetroxide and uranyl acetate and
epoxy embedded. Semi-thin sections were prepared and
stained with toluidine blue to select Purkinje cell con-
taining areas for ultrathin sections. Ultrathin sections
were stained with lead citrate and images of individual
Purkinje cells (about 20 per animal if possible) were ac-
quired with the JEM-1400 (JEOL, Tokyo, Japan) at a
lower magnification to show the whole cell body and a
higher magnification to visualize ER and Golgi struc-
tures. Purkinje cells were graded by three criteria,
namely darkened cytoplasm, ER/Golgi swelling and ir-
regular cell shape, on a scale of each 0 (normal) to 2
(prominently altered). Cells that had the score 2 in at
least 2 criteria were regarded as degenerating.
Image analysis and statistical analysis
Immunoblot densitometry and quantifications from mi-
croscopy images were performed with ImageJ. Statistical
analysis was performed with Graphpad Prism as indi-
cated in the specific figures.
Additional file
Additional file 1: Figure S1. Additional phenotypic characterization of
IKK2-CA and IKK2-DN mice. Figure S2. Additional immune cell markers
and proinflammatory genes characterizing IKK2-CA-induced cerebellar
neuroinflammation. Figure S3. Neuroinflammation is also found in other
brain regions, but neurodegeneration is restricted to the cerebellum.
Figure S4. Expression kinetics of inflammatory mediators upon transgene
inactivation in IKK2-CA mice. Figure S5. The IKK2-CA transgene is not
expressed in Purkinje cells or microglia. Figure S6. Local microglia activation
is not sufficient to drive Purkinje cell degeneration. Figure S7. Characterisation
of Bergmann glia specific expression of the IKK2-CA-IRES-GFP transgene in the
IKK2-CASept4 model. Figure S8. Characterization of glutamate transporter
expression in response to astroglial IKK2 activation. (PDF 20468 kb)
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